Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors Clinical Trial

Official title:

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Inoperable Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05894486
• Other study ID #: XT-XTR008-2-01
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 5, 2023
• Est. completion date: June 5, 2026

Study information

• Verified date: May 2023
• Source: Peking University
• Contact: Ming Lu, professor
• Phone: 86-10-88196561
• Email: qiminglu_mail[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

his was a single-center, single-arm phase II study evaluate the efficacy and safety of Lutetium[177Lu] Oxodotreotide Injection in the first-line treatment of unresectable or metastatic, progressive, G2 or G3, somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours.

Description:

After the screening period, participants who signed the ICF and were eligible for the study in accordance with the entry criteria were assigned to treatment with Lutetium[177Lu] Oxodotreotide Injection. Objective tumor assessment in both groups was performed every 12+/-1 weeks from the first treatment date according to RECIST 1.1 Criteria until progression.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: June 5, 2026
• Est. primary completion date: June 5, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Ability to understand and willingness to sign a written informed consent document.

2. Aged 18-75 years.

3. Histopathologically confirmed G2 or G3 unresectable locally advanced or metastatic GEP-NET, Ki67 index =10 and = 55%. (based on the fifth edition of the WHO classification and grading criteria for neuroendocrine, tumors of the digestive system in 2019, to be centrally confirmed).

4. Subjects have not received prior systemic antitumor therapy for the current stage of NET.

5. Presence of at least 1 measurable site of disease (based on RECIST 1.1).

6. All target lesions (based on RECIST 1.1) at baseline must be confirmed as growth inhibitor receptor positive by 68Ga-Dotatate PET/CT.

7. ECOG score of 0 or 1.

8. Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, IUDs, etc., during treatment and within 3 months of the last use of the trial drug.

Exclusion Criteria:

1. Serum creatinine >150 µmol/L (1.7 mg/dL) or creatinine clearance <50 ml/min (Cockcroft Gault formula).

2. Hemoglobin <80g/L, or white blood cell count <2.0×109/L, or platelets <75×109/L.

3. Serum total bilirubin > 3 × upper limit of normal (ULN).

4. Serum albumin <30g/L.

5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5×ULN.

6. International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 x ULN.

7. Pregnant or lactating females.

8. Received peptide receptor radionuclide therapy(PRRT) prior to randomization.

9. Received the following treatments within 4 weeks prior to treatment, including but not limited to surgery (except biopsy), radical radiotherapy, hepatic artery interventional embolization, cryoablation of liver metastases, or radiofrequency ablation.

10. Received systemic antitumor therapy such as targeted therapy, immunotherapy, antitumor herbal therapy, chemotherapy within 4 weeks prior to randomization.

11. Toxicity of prior antitumor therapy has not returned to = grade 1 levels (except for alopecia).

12. Received external beam radiation therapy for bone metastases within 2 weeks prior to treatment.

13. More than 25% of bone marrow with prior external radiation radiotherapy.

14. Known brain metastases, unless these metastases have been treated and stabilized for at least 24 weeks, prior to enrollment in the study.

15. Uncontrolled congestive heart failure.

16. uncontrolled diabetes mellitus, including baseline fasting glucose > 2 x ULN.

17. Any patient receiving treatment with short-acting Octreotide, which cannot be interrupted for 24 h before and 24 h after the administration of Lutetium[177Lu] Oxodotreotide Injection, or any patient receiving treatment with Octreotide LAR, which cannot be interrupted for at least 6 weeks before the administration of Lutetium[177Lu] Oxodotreotide Injection.

18. Known other malignancies (except for those without recurrence within 5 years after adequate treatment)

19. Known hypersensitivity to Lutetium[177Lu] Oxodotreotide Injection or oxytetracycline acetate microsphere components and their excipients.

20. Known to be unsuitable for enhanced CT or MRI contrast imaging due to allergic reaction or renal insufficiency

21. Any clinically significant active infection, including Positive human immunodeficiency virus (HIV) antibody.

22. Positive for hepatitis B virus (HBV) surface antigen (HBsAg) and positive for HBV DNA (=1×104 copies/ml or judged positive by research center criteria), or positive for hepatitis C virus (HCV) antibodies.

23. Participated in other drug clinical trials within 4 weeks prior to the first treatment and received treatment with the corresponding trial drug.

24. Any other disease, mental status or surgical condition that is uncontrolled, may interfere with study completion (including poor compliance) or is inappropriate for the use of the investigational drug.

25. Other treatment options (e.g., chemotherapy, targeted therapy) that, in the opinion of the investigator, are more appropriate for the patient than the treatment provided in the study based on the patient's disease characteristics, i.e., the investigational drug is not the best therapeutic agent for clinical practice.

26. Subjects who, in the judgment of the investigator, are suspected of having a disease or condition that makes them unsuitable for the study drug disease or condition.

Related Conditions & MeSH terms

• Neuroendocrine Tumors

Intervention

Drug:
• Lutetium[177Lu] Oxodotreotide Injection
Lutetium[177Lu] Oxodotreotide InjectionFour administrations of 7.4 GBq (200 mCi) Lutetium[177Lu] Oxodotreotide Injection administered at 8 +/- 1-week intervals, which could be extended up to 16 weeks to accommodate resolving acute toxicity

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Peking University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 in all participants	ORR is defined as the percentage of participants in the analysis population who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: =30% decrease in the sum of diameters of target lesions) per RECIST 1.1. For this analysis, ORR will be assessed in all participants	Up to 2 years
Secondary	Incidence of Treatment-Related Adverse Events	An AE was defined as any untoward medical occurrence in a participant administered a study treatment and which does not necessarily have to have a causal relationship with this treatment. The number of participants who experienced =1 AE will be presented.	Until 30 days after the last treatment
Secondary	Progression-free Survival (PFS) per RECIST 1.1 in all participants	PFS is defined as the time from the date of first dose to the first documented disease	Up to 2 years
Secondary	Disease control rate(DCR)		Up to 2 years